600056 中国医药
2026/09 - 九个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)2.4403.9664.9399.3686.982
总资产报酬率 ROA (%)0.7701.2931.5802.8592.196
投入资产回报率 ROIC (%)1.2602.0782.5394.7343.594

边际利润分析
销售毛利率 (%)10.42410.50210.73611.29112.627
营业利润率 (%)2.4662.8932.7994.3073.191
息税前利润/营业总收入 (%)3.1153.1373.4614.5143.550
净利润/营业总收入 (%)1.5651.9082.0823.1992.363

收益指标分析
经营活动净收益/利润总额(%)115.288125.012121.41680.615121.618
价值变动净收益/利润总额(%)2.831-7.0276.288-0.9034.425
营业外收支净额/利润总额(%)-0.167-2.3712.139-1.937-0.299

偿债能力分析
流动比率 (X)1.4301.4231.5231.5841.495
速动比率 (X)1.1311.1161.1741.2381.158
资产负债率 (%)62.36961.04460.55862.87763.312
带息债务/全部投入资本 (%)40.08237.48237.75735.64538.609
股东权益/带息债务 (%)125.592141.545137.049143.241129.484
股东权益/负债合计 (%)49.79852.58754.68749.14747.581
利息保障倍数 (X)4.77010.0835.76715.6439.648

营运能力分析
应收账款周转天数 (天)161.378138.467137.172125.141116.446
存货周转天数 (天)73.76570.25671.59064.36664.338